Free Trial
NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

Context Therapeutics logo
$2.27
+0.09 (+4.13%)
(As of 11/1/2024 ET)

About Context Therapeutics Stock (NASDAQ:CNTX)

Key Stats

Today's Range
$2.20
$2.30
50-Day Range
$1.71
$2.50
52-Week Range
$0.77
$2.75
Volume
126,622 shs
Average Volume
313,474 shs
Market Capitalization
$170.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25
Consensus Rating
Buy

Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
61st Percentile Overall Score

CNTX MarketRank™: 

Context Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 495th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Context Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Context Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Context Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.32) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Context Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Context Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Context Therapeutics has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Context Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.74% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Context Therapeutics has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Context Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Context Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.74% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Context Therapeutics has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Context Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Context Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for CNTX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.04% of the stock of Context Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 14.03% of the stock of Context Therapeutics is held by institutions.

  • Read more about Context Therapeutics' insider trading history.
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
Piper Sandler Keeps Their Buy Rating on Context Therapeutics (CNTX)
See More Headlines

CNTX Stock Analysis - Frequently Asked Questions

Context Therapeutics' stock was trading at $1.13 at the beginning of the year. Since then, CNTX shares have increased by 100.9% and is now trading at $2.27.
View the best growth stocks for 2024 here
.

Context Therapeutics Inc. (NASDAQ:CNTX) issued its earnings results on Wednesday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.04.

Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
8/07/2024
Today
11/02/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTX
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.25
High Stock Price Target
$10.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+175.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.74 per share

Miscellaneous

Free Float
72,718,000
Market Cap
$170.25 million
Optionable
Not Optionable
Beta
2.27
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:CNTX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners